PEMAZYRE 13.5 mg, tablet 14 tablets
Active ingredients: PÉMIGATINIB
Commercialized according to BDPMDispensing in France: Prescription only
Tablet14 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- PEMAZYRE 13,5 mg, comprimé
- Pharmaceutical form
- comprimé
- Route of administration
- orale
- Presentation description
- plaquette(s) (ACLAR RX) polytrifluorochloroéthylène PVC papier aluminium de 14 comprimé(s)
- Marketing authorisation holder
- INCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 31 Mar 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
67695203CIP73022371CIP133400930223710Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PÉMIGATINIBcomprimé | 13,5 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.